These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

303 related items for PubMed ID: 25490355

  • 1. [Laboratory assessment of haemostatic parameters in patients taking a direct thrombin inhibitor].
    Beliavskaia OO, Vavilova TV.
    Angiol Sosud Khir; 2014; 20(4):37-41. PubMed ID: 25490355
    [Abstract] [Full Text] [Related]

  • 2. [Dabigatran therapy--perioperative management and interpretation of coagulation tests].
    Spannagl M, Bauersachs R, Debus ES, Gawaz M, Gerlach H, Haas S, Hach-Wunderle V, Lindhoff-Last E, Riess H, Schellong S, Schinzel H, Bode C.
    Hamostaseologie; 2012; 32(4):294-305. PubMed ID: 23114798
    [Abstract] [Full Text] [Related]

  • 3. [Dabigatran eteksilat new anticoagulant for the prevention of stroke in patients with atrial fibrillation without valvular lesions].
    Panchenko EP.
    Kardiologiia; 2011; 51(11):83-90. PubMed ID: 22117775
    [No Abstract] [Full Text] [Related]

  • 4. Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013.
    Pernod G, Albaladejo P, Godier A, Samama CM, Susen S, Gruel Y, Blais N, Fontana P, Cohen A, Llau JV, Rosencher N, Schved JF, de Maistre E, Samama MM, Mismetti P, Sié P, Working Group on Perioperative Haemostasis.
    Arch Cardiovasc Dis; 2013; 106(6-7):382-93. PubMed ID: 23810130
    [Abstract] [Full Text] [Related]

  • 5. Modeling of the impact on health outcomes of the use of dabigatran in patients with atrial fibrillation.
    Chevalier J, Giroud M, de Pouvourville G.
    Cerebrovasc Dis; 2013; 35(4):320-6. PubMed ID: 23615428
    [Abstract] [Full Text] [Related]

  • 6. Atrial fibrillation and dabigatran: has the time come to use new anticoagulants?
    Escobar C, Barrios V, Jimenez D.
    Cardiovasc Ther; 2010 Oct; 28(5):295-301. PubMed ID: 20718760
    [Abstract] [Full Text] [Related]

  • 7. Dabigatran for stroke prevention in atrial fibrillation.
    Hohnloser SH, Diener HC.
    Hamostaseologie; 2012 Oct; 32(3):216-20. PubMed ID: 22739760
    [Abstract] [Full Text] [Related]

  • 8. Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation: the RE-LY study and substudies with commentary.
    Waks JW, Zimetbaum PJ.
    Expert Rev Cardiovasc Ther; 2013 Nov; 11(11):1461-71. PubMed ID: 24147516
    [Abstract] [Full Text] [Related]

  • 9. New oral antithrombotics: focus on dabigatran, an oral, reversible direct thrombin inhibitor for the prevention and treatment of venous and arterial thromboembolic disorders.
    Dahl OE.
    Vasc Health Risk Manag; 2012 Nov; 8():45-57. PubMed ID: 22323896
    [Abstract] [Full Text] [Related]

  • 10. Home-monitoring of oral anticoagulation vs. dabigatran. An indirect comparison.
    Alonso-Coello P, Zhou Q, Guyatt G.
    Thromb Haemost; 2012 Oct; 108(4):647-53. PubMed ID: 22918481
    [Abstract] [Full Text] [Related]

  • 11. Dabigatran and factor Xa inhibitors for stroke prevention in patients with nonvalvular atrial fibrillation.
    Uchiyama S, Ibayashi S, Matsumoto M, Nagao T, Nagata K, Nakagawara J, Tanahashi N, Tanaka K, Toyoda K, Yasaka M.
    J Stroke Cerebrovasc Dis; 2012 Apr; 21(3):165-73. PubMed ID: 22440950
    [Abstract] [Full Text] [Related]

  • 12. [Dabigatran in the prevention of stroke in nonvalvular atrial fibrillation: complex clinical situations and real clinical practice].
    Tkacheva ON, Akasheva DU.
    Ter Arkh; 2014 Apr; 86(4):103-7. PubMed ID: 24864477
    [Abstract] [Full Text] [Related]

  • 13. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice.
    Huisman MV, Lip GY, Diener HC, Brueckmann M, van Ryn J, Clemens A.
    Thromb Haemost; 2012 May; 107(5):838-47. PubMed ID: 22318514
    [Abstract] [Full Text] [Related]

  • 14. Dabigatran: a new option for anticoagulation in atrial fibrillation and venous thromboembolism.
    Acharjee S, Cannon CP.
    Crit Pathw Cardiol; 2011 Jun; 10(2):84-6. PubMed ID: 21988948
    [Abstract] [Full Text] [Related]

  • 15. The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study.
    Connolly SJ, Wallentin L, Ezekowitz MD, Eikelboom J, Oldgren J, Reilly PA, Brueckmann M, Pogue J, Alings M, Amerena JV, Avezum A, Baumgartner I, Budaj AJ, Chen JH, Dans AL, Darius H, Di Pasquale G, Ferreira J, Flaker GC, Flather MD, Franzosi MG, Golitsyn SP, Halon DA, Heidbuchel H, Hohnloser SH, Huber K, Jansky P, Kamensky G, Keltai M, Kim SS, Lau CP, Le Heuzey JY, Lewis BS, Liu L, Nanas J, Omar R, Pais P, Pedersen KE, Piegas LS, Raev D, Smith PJ, Talajic M, Tan RS, Tanomsup S, Toivonen L, Vinereanu D, Xavier D, Zhu J, Wang SQ, Duffy CO, Themeles E, Yusuf S.
    Circulation; 2013 Jul 16; 128(3):237-43. PubMed ID: 23770747
    [Abstract] [Full Text] [Related]

  • 16. CHA2DS2-VASc and HAS-BLED scores and activated partial thromboplastin time for prediction of high plasma concentration of dabigatran at trough.
    Owada S, Tomita H, Kinjo T, Ishida Y, Itoh T, Sasaki K, Horiuchi D, Kimura M, Sasaki S, Okumura K.
    Thromb Res; 2015 Jan 16; 135(1):62-7. PubMed ID: 25466835
    [Abstract] [Full Text] [Related]

  • 17. Dabigatran for the prevention and treatment of thromboembolic disorders.
    Enriquez A, Baranchuk A, Redfearn D, Simpson C, Abdollah H, Michael K.
    Expert Rev Cardiovasc Ther; 2015 May 16; 13(5):529-40. PubMed ID: 25843430
    [Abstract] [Full Text] [Related]

  • 18. A new era of oral anticoagulation in atrial fibrillation: implications in clinical practice.
    Kasmeridis C, Lip GY, Apostolakis S.
    Hosp Pract (1995); 2013 Feb 16; 41(1):61-70. PubMed ID: 23466968
    [Abstract] [Full Text] [Related]

  • 19. Bleeding events and activated partial thromboplastin time with dabigatran in clinical practice.
    Kawabata M, Yokoyama Y, Sasano T, Hachiya H, Tanaka Y, Yagishita A, Sugiyama K, Nakamura T, Suzuki M, Isobe M, Hirao K.
    J Cardiol; 2013 Aug 16; 62(2):121-6. PubMed ID: 23680005
    [Abstract] [Full Text] [Related]

  • 20. [Comparison of the safety of rivaroxaban versus dabigatran therapy in patients with persistent atrial fibrillation].
    Gorzelak-Pabiś P, Duraj I, Szlagowska L, Ciastkowska A, Broncel M.
    Pol Merkur Lekarski; 2014 Nov 16; 37(221):261-4. PubMed ID: 25546985
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.